Verve Therapeutics, Inc. - Common Stock (VERV)

Let's have a look at the stocks with an unusual volume in today's session.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Verve shares Phase 1b results of VERVE-102, showing dose-dependent LDL-C reductions and strong safety in patients with HeFH or premature CAD.

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

VERV stock results show that Verve Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.

On Monday, Cathie Wood-led Ark Invest made some significant trades, with Coinbase Global Inc. (NASDAQ:COIN) taking the spotlight. This comes amidst a turbulent market scenario, particularly for cryptocurrencies. The COIN Trade

Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Video Communications Inc (NASDAQ:ZM).

On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a recent trend of the investment firm adjusting its portfolio.

Cathie Wood's flagship ARK Innovation ETF has been navigating through significant losses, showcasing the challenges faced by some of its major holdings.

Discover three biotech stocks handpicked by Cathie Wood, offering groundbreaking therapies and substantial growth potential.

10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line.

VERV stock results show that Verve Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.